Floatz logo

Lorlatinib

Recurrent Myelodysplastic Syndrome

OHSU Knight Cancer InstituteSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

315 Active assets in the Recurrent Myelodysplastic Syndrome cohort.

Asset / SponsorPhaseRating
Fludarabine
Sawa Ito, MD
Phase 4BB
Anti-Thymoglobulin, Rabbit
Peking University First Hospital
Phase 2/3BB
Cytosin-Arabinosid
The First Affiliated Hospital of Soochow University
Phase 4BB
FILGRASTIM
City of Hope Medical Center
Phase 4BB
Daunorubicin
OHSU Knight Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

Lorlatinib is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
hepatocellular carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
neoplastic meningitisDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →